Mecbotamab vedotin (BA3011) is an AXL-targeting, conditionally active biologic antibody-drug conjugate that delivers the cytotoxic agent monomethyl auristatin E (MMAE).15,16 BA3011 is designed to bind to AXL under tumor-specific conditions of accelerated glycolytic metabolism.15-17 Considering that AXL is expressed physiologically in many tissues, CAB-ADCs have the potential advantage of increased tumor specificity.15-17. Here, AXL is linked to neoplasm.